Is Definitely Ra Medical Systems a Good Penny Stock to Purchase?

The shares of commercial-stage medical gadget manufacturer Ra Medical Systems (RMED) have actually tumbled 92.7% in cost over the past year because of financier concerns bordering the company’s bad economic health and wellness. Also, provided the uncertainty surrounding the FDA’s authorization of its DABRA catheter laser system, the question becomes, is the penny stock a winner currently? Continue reading, let’s find out.

Medical tool company Ra Medical Systems, Inc. (RMED – Get Ranking) in Carlsbad, Calif., is styles, creates, and markets excimer lasers to treat vascular diseases. The business has made considerable progress in essential campaigns, including its DABRA technology laser system and also atherectomy essential professional study. However, the stock RMED has actually decreased 86.8% in cost over the past 6 months and also 92.7% over the past year, showing financier worries over its disappointing income and earnings growth as well as the sale of its dermatology organization.

Closing yesterday’s session at $0.42, the stock is presently trading 95.7% listed below its 52-week high of $9.82, showing bearish view.

While the commercial-stage medical tool company has actually submitted a 510( k) application with the united state Food and Drug Administration (FDA) for its DABRA catheter, its commercialization leads continue to be uncertain until its product gets approval from the FDA. Moreover, the stock’s negative success could make financiers distressed.

Marketing Shares

Last month, RMED valued an underwritten public offering of systems of its common stock, consisting of warrants to buy approximately 27.6 million shares of the ordinary shares and also pre-funded warrants to acquire as much as 14.47 shares of penny stocks. The medical gadget supplier anticipates approximately $12.1 million in gross earnings from the offering.

Divestiture of Dermatology Company

Leading 10 Stocks for 2022
In the 3rd quarter, RMED completed the sale of its Pharos dermatology company for web earnings of approximately $3.5 million. This was done as a part of the business’s plans to focus its resources on the market for medical devices to treat peripheral artery disease (PAD). Nonetheless, the divestiture might negatively influence the medical device maker’s revenues and cost structure in the near term and trigger RMED’s stock price to topple further.

Grim Profitability

The firm’s trailing-12-month ROA as well as cash money from procedures are negative 100.6% as well as $31.33 million, respectively. In addition, its trailing-12-month gross profit margin, ROE and also ROTC are unfavorable 18.9%, 115%, as well as 67%, specifically. And also its 0.12% property turnover proportion is 65.2% lower than the 0.34% sector standard.

Failing Financials
RMED’s net earnings from proceeding operations came in at $5,000 for the 3rd quarter, finished Sept. 30, 2021, versus $68,000 in the third quarter of 2020. Its gross loss stood at $24,000 for the quarter, while operating loss came in at $7.39 million. Moreover, its net loss totaled up to $4.3 million, while its loss per share can be found in at $0.67. RMED reported an adverse modified EBITDA of $6.95 million versus $6.06 million in the prior-year quarter. And also its overall general expenses expanded 2.1% year-over-year to $7.15 million throughout this period.

POWR Scores Reflect Bleak Potential Customers

RMED has a general D rating, which converts to Market in our POWR Scores system. The POWR Ratings are computed by thinking about 118 unique aspects, with each aspect weighted to an ideal level.

Our exclusive ranking system likewise reviews each stock based on eight unique categories. RMED has an F grade for High quality. This mirrors the stock’s negative ROA as well as capital from operations.

The firm has a D grade in Momentum, regular with its rate decline over the past 6 months. Additionally, it has an F quality for Stability, which remains in sync with its fairly high beta of 1.65.

Beyond the grades I have actually highlighted, one can take a look at extra RMED ratings for Belief, Growth, and Value here. Amongst the 166 stocks in the D-rated Medical– Gadget & Equipment market, RMED is placed # 119.


Experts anticipate RMED’s EPS to stay negative this year. While its initiatives to develop DABRA catheters bode well, its adverse revenue margin as well as insufficient financial strength might trigger its shares to decrease better. Moreover, the unpredictability surrounding the regulatory clearance and commercialization of its DABRA laser system can elevate investors’ issues. So, we believe it is ideal stayed clear of currently.

Just How Does Ra Medical Systems (RMED) Stack Up Against its Peers?

While RMED has an overall D (Offer) score in our exclusive ranking system, one could want to consider taking a look at its sector peers, Fonar Firm (FONR – Obtain Score), Electromed, Inc. (ELMD – Get Ranking), and Abbott Laboratories (ABT – Obtain Ranking), having an A (Solid Buy) rating.